Testing KIO-104 eye injection for macular edema
Part of Eyes & vision clinical trials.
This trial tests an eye injection called KIO-104 to treat macular edema (swelling in the center of the retina) caused by conditions like uveitis, diabetes, or vein blockage. The goal is to see if it is safe and improves vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 85 years old.
- You must have macular edema in at least one eye from uveitis, diabetes, vein blockage, or cataract surgery.
- The swelling in your eye must be at least a certain thickness (350 microns) measured by a scan.
- Your vision in the study eye must be between 20/800 and 20/32.
- If you take steroids or other immune-suppressing medications by mouth, the dose must be stable for 3 months before and during the study.
- You cannot have had certain other eye treatments or surgeries in the study eye in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental medication (BI 1815368) given as an eye injection for people with diabetic macular edema, a condition where fluid builds up in the center of the retina and blurs vision. The study aims to see if this new treatment can reduce swelling and improve vision.
This trial tests if a new medicine (MK-8748) works as well as or better than the usual treatment (aflibercept) for people with diabetic macular edema, a condition that causes vision loss from diabetes-related swelling in the back of the eye.
This trial tests an eye injection called KIO-301 for people with late-stage retinitis pigmentosa (a genetic eye disease that causes vision loss). The goal is to see if it can improve vision or slow further vision loss.
This Phase 1 trial tests whether BBC1501, an injection given into the eye, is safe for people with wet age-related macular degeneration (nAMD). It mainly looks at side effects and whether the study injections can be given safely in patients who still have active disease despite prior anti-VEGF treatments.
This trial tests a new injected medicine (KSI-101) for people with swelling in the back of the eye caused by inflammation. The medicine is given directly into the eye to see if it can reduce the swelling and improve vision.
This trial tests a new medicine called KSI-101 given as an injection into the eye to treat swelling in the center of the retina caused by inflammation. It may help people whose vision has gotten worse due to this type of swelling.
Hear when a new Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.